The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms.

Interestingly, though the OS between the axitinib and placebo group did not reach statistical significance, the authors found the OS was better in some subgroups, such as Eastern Cooperative Oncology Group performance status (ECOG PS) 1, excluding those intolerant to prior antiangiogenic therapy, as well as those patients with baseline α-fetoprotein ≥400 ng/ml.

also in 111,027 other papers